Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer

You may be eligible if

• Histologically or cytologically confirmed colorectal cancer (advanced or metastatic disease not amenable to potential curative resection)
• Archival tumor (blocks and/or slides) must be available for patients who decline tumor biopsies
• Tumor must be amenable to sequential biopsies for patients willing to undergo tumor biopsy
• Must have evidence of disease progression after first-line chemotherapy for advanced disease
• Previously irradiated lesions are not considered measurable disease
• Measurable disease, defined as \>= 1 unidimensionally measurable target lesion \>= 20 mm by conventional techniques OR \>= 10 mm by spiral CT scan
• No known brain metastases
• Eastern Cooperative Oncology Group (ECOG) 0-2 OR Karnofsky 60-100%
• Life expectancy of more than 12 weeks
• white blood cell count (WBC) \>= 3,000/mm\^3
• Bilirubin normal
• Creatinine normal OR creatinine clearance \>= 60 mL/min
• No hypertension
• No symptomatic congestive heart failure
• No unstable angina pectoris
• No cardiac arrhythmia
• Not pregnant or nursing
• Able to swallow oral medication
• Willing to undergo 2 sequential tumor and skin biopsies
• No ongoing or active infection
• No history of allergic reaction attributed to compounds of similar chemical or biologic composition to study drugs
• No psychiatric illness or social situation that would preclude study compliance
• No other uncontrolled illness
• No prior cetuximab
• No concurrent prophylactic filgrastim (G-CSF), sargramostim (GM-CSF) or epoetin alfa
• At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
• No other concurrent chemotherapy
• More than 4 weeks since prior radiotherapy and recovered
• No prior sorafenib
• No other prior therapy targeted against MAPK
• More than 14 days since prior and no concurrent administration of the following cytochrome P450 3A4 (CYP3A4) inducers:
• * Rifampin
• * Rifabutin
• * Hypericum perforatum (St. John's wort)
• * Phenytoin
• * Carbamazepine
• * Phenobarbital
• More than 7 days since prior and no concurrent administration of the following CYP3A4 inhibitors:
• * Amiodarone
• * Clarithromycin
• * Diltiazem
• * Erythromycin
• * Grapefruit juice
• * Indinavir
• * Saquinavir
• * Lopinavir in combination with ritonavir
• * Fosamprenavir
• * Ritonavir
• * Atazanavir
• * Nelfinavir
• * Itraconazole
• * Ketoconazole
• * Nefazodone
• No concurrent combination antiretroviral therapy for HIV-positive patients
• No other concurrent investigational agents
• No other concurrent anticancer therapy
• Negative pregnancy test
• Fertile patients must use effective contraception
• Absolute neutrophil count \>=1,500/mm\^3
• Platelet count ≥ 100,000/mm\^3
• No evidence of bleeding diathesis
• Aspartate aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤ 2.5 times upper limit of normal